Merck The Other Clock Merck's sac-TMT cut the risk of death by 32% in recurrent endometrial cancer, with median survival of 19 months versus 12.1. An FDA decision is expected in June 2027.
intismeran The Vial From the Tumour A personalised mRNA vaccine added to pembrolizumab cut melanoma recurrence or death by 42 percent in a phase 3 trial of 1,137 people. Overall survival is not yet shown.
